Growth Metrics

Vericel (VCEL) Gross Margin (2011 - 2026)

Vericel recorded quarterly Gross Margin of 72.0% in Q1 2026, down 8.52% quarter-over-quarter from 78.7% in Q4 2025, and up 304.0% year-over-year from 17.82% in Q1 2025.

Vericel's Gross Margin history runs 16 years deep, the most recent figure standing at 72.0% for Q1 2026.

  • In Q1 2026, Gross Margin rose 304.0% year-over-year to 72.0%; the TTM figure through Mar 2026 stood at 74.84% (up 230.0% YoY), while the FY2025 annual figure was 74.42%, up 187.0% from the prior year.
  • Gross Margin came in at 72.0% for Q1 2026 at Vericel, down from 78.7% in the prior quarter.
  • In the past five years, Gross Margin ranged from a high of 78.7% in Q4 2025 to a low of 61.69% in Q2 2022.
  • A 5-year average of 70.09% and a median of 69.5% in 2024 frame the typical range for Gross Margin.
  • Across the five-year window, Gross Margin plunged 640 bps in 2022 and jumped 478 bps in 2024, its largest moves.
  • Vericel's Gross Margin stood at 72.59% in 2022, then gained by 3 bps to 74.63% in 2023, then gained by 4 bps to 77.61% in 2024, then climbed by 1 bps to 78.7% in 2025, then retreated by 9 bps to 72.0% in 2026.
  • According to Business Quant data, Gross Margin over the past three periods registered 72.0%, 78.7%, and 73.46% for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Gross Margin (Qtr)
1 Quantum Biopharma 1,216,509.61 Bn 1,216,509.61 Bn - -
2 Alterity Therapeutics 764,224.41 Bn 764,224.38 Bn - -
3 Legend Biotech 2,716.00 Bn 2,715.71 Bn 242.10 Mn 79.04%
4 Nanobiotix 2,248.83 Bn 2,248.77 Bn - -
5 Akari Therapeutics 1,951.18 Bn 1,951.17 Bn - -
6 Vertex Pharmaceuticals 113.69 Bn 106.44 Bn 2.59 Bn 86.85%
7 Evaxion A 64.16 Bn 64.14 Bn - -
8 Regeneron Pharmaceuticals 63.94 Bn 55.18 Bn 3.31 Bn 91.79%
9 Alnylam Pharmaceuticals 40.13 Bn 37.12 Bn 959.66 Mn 82.22%
10 Vericel 1.69 Bn 1.55 Bn 49.27 Mn 72.00%

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 72.00%
Dec 31, 2025 78.70%
Sep 30, 2025 73.46%
Jun 30, 2025 73.71%
Mar 31, 2025 68.96%
Dec 31, 2024 77.61%
Sep 30, 2024 71.93%
Jun 30, 2024 69.50%
Mar 31, 2024 68.94%
Dec 31, 2023 74.63%
Sep 30, 2023 67.15%
Jun 30, 2023 65.20%
Mar 31, 2023 64.66%
Dec 31, 2022 72.59%
Sep 30, 2022 65.45%
Jun 30, 2022 61.69%
Mar 31, 2022 65.41%
Dec 31, 2021 71.51%
Sep 30, 2021 64.04%
Jun 30, 2021 68.09%
Mar 31, 2021 68.35%
Dec 31, 2020 74.39%
Sep 30, 2020 69.66%
Jun 30, 2020 56.73%
Mar 31, 2020 62.81%
Dec 31, 2019 73.13%
Sep 30, 2019 69.43%
Jun 30, 2019 65.50%
Mar 31, 2019 60.39%
Dec 31, 2018 72.46%
Sep 30, 2018 63.81%
Jun 30, 2018 59.36%
Mar 31, 2018 57.47%
Dec 31, 2017 64.07%
Sep 30, 2017 49.61%
Jun 30, 2017 54.76%
Mar 31, 2017 24.06%
Dec 31, 2016 64.07%
Sep 30, 2016 37.27%
Jun 30, 2016 43.07%
Mar 31, 2016 53.50%
Dec 31, 2015 53.12%
Sep 30, 2015 40.12%
Jun 30, 2015 49.22%
Mar 31, 2015 48.68%
Dec 31, 2014 54.09%
Sep 30, 2014 42.72%
Jun 30, 2014 -13.02%
Dec 31, 2013 87.50%
Jun 30, 2013 66.67%
Mar 31, 2013 75.00%
Dec 31, 2012 78.95%
Sep 30, 2011 77.78%
Mar 31, 2011 77.78%